Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273389 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01273389: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT01273389 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01273389, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
Primary Outcome
It is measured as the percentage in reduction of proteinuria from baseline to Week 24.
Interventions
- DRUG Placebo
- DRUG CNTO 136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01273389 record still lists
NCT01273389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01273389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01273389 about?
NCT01273389 is a clinical study titled "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis". The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
What is the current status of trial NCT01273389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01273389?
The interventions under investigation include: Placebo (DRUG), CNTO 136 (DRUG).
Who is sponsoring clinical trial NCT01273389?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01273389's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia